Impact of patient complication and treatment utilities on the difference in QALYs of intensive glucose control versus conventional glucose control in older patients*
| Age at onset (years) . | Difference in costs (in dollars) . | Difference in QALYs . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Complication utilities . | . | . | . | . | . | |||||
| . | . | Original . | Patient . | Original . | Patient . | Original . | Patient . | |||||
| . | . | Treatment utilities . | . | . | . | . | . | |||||
| . | . | Original . | Original . | Patient, insulin . | Patient, insulin . | Patient, orals . | Patient, orals . | |||||
| 60–65 | 16,036 | 0.12 | 0.206 (0.198–0.213) | −1.04 (−1.25 to −0.82) | −0.96 (−1.18 to −0.75) | 0.18 (0.01–0.35) | 0.24 (0.07–0.41) | |||||
| 65–70 | 14,154 | 0.043 | 0.084 (0.081–0.088) | −0.88 (−1.06 to −0.70) | −0.84 (−1.02 to −0.67) | 0.11 (−0.03 to 0.25) | 0.14 (0.003–0.28) | |||||
| 70–75 | 12,185 | 0.016 | 0.034 (0.033–0.036) | −0.73 (−0.87 to −0.58) | −0.71 (−0.86 to −0.57) | 0.081 (−0.033 to 0.20) | 0.096 (−0.018 to 0.21) | |||||
| 75–80 | 9,897 | 0.0043 | 0.0104 (0.0098–0.0109) | −0.57 (−0.69 to −0.46) | −0.57 (−0.68 to −0.46) | 0.060 (−0.029 to 0.15) | 0.065 (−0.024 to 0.15) | |||||
| 80–85 | 7,310 | 0.00097 | 0.00256 (0.00242–0.00270) | −0.42 (−0.50 to −0.34) | −0.41 (−0.50 to −0.33) | 0.046 (−0.019 to 0.11) | 0.048 (−0.017 to 0.11) | |||||
| 85–90 | 4,962 | 0.00021 | 0.000557 (0.000527–0.000587) | −0.29 (−0.34 to −0.23) | −0.28 (−0.34 to −0.23) | 0.035 (−0.010 to 0.08) | 0.037 (−0.008 to 0.082) | |||||
| Age at onset (years) . | Difference in costs (in dollars) . | Difference in QALYs . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Complication utilities . | . | . | . | . | . | |||||
| . | . | Original . | Patient . | Original . | Patient . | Original . | Patient . | |||||
| . | . | Treatment utilities . | . | . | . | . | . | |||||
| . | . | Original . | Original . | Patient, insulin . | Patient, insulin . | Patient, orals . | Patient, orals . | |||||
| 60–65 | 16,036 | 0.12 | 0.206 (0.198–0.213) | −1.04 (−1.25 to −0.82) | −0.96 (−1.18 to −0.75) | 0.18 (0.01–0.35) | 0.24 (0.07–0.41) | |||||
| 65–70 | 14,154 | 0.043 | 0.084 (0.081–0.088) | −0.88 (−1.06 to −0.70) | −0.84 (−1.02 to −0.67) | 0.11 (−0.03 to 0.25) | 0.14 (0.003–0.28) | |||||
| 70–75 | 12,185 | 0.016 | 0.034 (0.033–0.036) | −0.73 (−0.87 to −0.58) | −0.71 (−0.86 to −0.57) | 0.081 (−0.033 to 0.20) | 0.096 (−0.018 to 0.21) | |||||
| 75–80 | 9,897 | 0.0043 | 0.0104 (0.0098–0.0109) | −0.57 (−0.69 to −0.46) | −0.57 (−0.68 to −0.46) | 0.060 (−0.029 to 0.15) | 0.065 (−0.024 to 0.15) | |||||
| 80–85 | 7,310 | 0.00097 | 0.00256 (0.00242–0.00270) | −0.42 (−0.50 to −0.34) | −0.41 (−0.50 to −0.33) | 0.046 (−0.019 to 0.11) | 0.048 (−0.017 to 0.11) | |||||
| 85–90 | 4,962 | 0.00021 | 0.000557 (0.000527–0.000587) | −0.29 (−0.34 to −0.23) | −0.28 (−0.34 to −0.23) | 0.035 (−0.010 to 0.08) | 0.037 (−0.008 to 0.082) | |||||
Data are means (95% CIs). Columns 3–8 illustrate the impact of distinct combinations of original and patient utilities on the expected health benefit (difference in QALYs) of intensive glucose control versus conventional glucose control for hypothetical patients, 65–90 years of age at disease onset. Insulin, utility for intensive glucose control with insulin used; orals, utility for intensive glucose control with oral medications used.